Drug Profile
Cinhyaluronate sodium - Seikagaku Corporation
Alternative Names: Hyaluronic acid ophthalmic - Seikagaku Corporation; Modified hyaluronate - Seikagaku Corporation; SI-614Latest Information Update: 18 May 2023
Price :
$50
*
At a glance
- Originator Seikagaku Corporation
- Class Eye disorder therapies; Glycosaminoglycans
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Dry eyes
Most Recent Events
- 18 May 2023 Seikagaku Corporation completes a phase III trial in Dry eye in USA (Ophthalmic) (NCT054113670)
- 08 Feb 2023 Seikagaku Corporation completes enrolment in its phase-III trial for Dry eyes in USA (Ophthalmic) (NCT05411367)
- 08 Feb 2023 Seikagaku Corporation plans a phase III trial for Dry eyes